Endologix, Inc. (ELGX) Expected to Post Quarterly Sales of $45.20 Million
Wall Street analysts expect Endologix, Inc. (NASDAQ:ELGX) to post $45.20 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Endologix’s earnings. The lowest sales estimate is $44.00 million and the highest is $45.70 million. Endologix reported sales of $47.46 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.8%. The company is expected to issue its next quarterly earnings report after the market closes on Wednesday, February 21st.
According to Zacks, analysts expect that Endologix will report full-year sales of $45.20 million for the current financial year, with estimates ranging from $181.10 million to $182.90 million. For the next financial year, analysts anticipate that the business will report sales of $188.24 million per share, with estimates ranging from $185.67 million to $191.20 million. Zacks’ sales averages are an average based on a survey of analysts that follow Endologix.
Endologix (NASDAQ:ELGX) last posted its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.06. Endologix had a negative net margin of 41.60% and a negative return on equity of 52.18%. The company had revenue of $45.99 million during the quarter, compared to analysts’ expectations of $47.21 million.
A number of hedge funds and other institutional investors have recently modified their holdings of ELGX. Schwab Charles Investment Management Inc. boosted its stake in Endologix by 10.5% during the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock worth $1,562,000 after acquiring an additional 30,429 shares in the last quarter. Rhumbline Advisers boosted its stake in Endologix by 0.4% during the second quarter. Rhumbline Advisers now owns 95,581 shares of the medical instruments supplier’s stock worth $465,000 after acquiring an additional 381 shares in the last quarter. Swiss National Bank lifted its stake in shares of Endologix by 14.3% in the second quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock valued at $670,000 after buying an additional 17,300 shares in the last quarter. Alliancebernstein L.P. lifted its stake in shares of Endologix by 11.5% in the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock valued at $529,000 after buying an additional 11,200 shares in the last quarter. Finally, Teachers Advisors LLC lifted its stake in shares of Endologix by 40.8% in the second quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock valued at $967,000 after buying an additional 57,675 shares in the last quarter.
Endologix (ELGX) traded down $0.03 on Tuesday, hitting $4.17. 548,948 shares of the stock traded hands, compared to its average volume of 588,985. Endologix has a 52 week low of $4.05 and a 52 week high of $7.66. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90. The firm has a market capitalization of $348.00, a PE ratio of -4.48 and a beta of 0.42.
TRADEMARK VIOLATION NOTICE: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/endologix-inc-elgx-expected-to-post-quarterly-sales-of-45-20-million/1844670.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.